NASDAQ: PXMDPaxmedica Inc Stock
$0.69-0.08 (-10.39%)
Updated Dec 8, 2023
PXMD Price
$0.69
Fair Value Price
$6.06
Market Cap
$1.59M
52 Week Low
$0.69
52 Week High
$69.19
P/E
-0.03x
P/B
-2.96x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$17.59M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-7.02
Operating Cash Flow
-$11M
Beta
0.62
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PXMD Overview
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PXMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PXMD ($0.69) is undervalued by 88.54% relative to our estimate of its Fair Value price of $6.06 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PXMD ($0.69) is significantly undervalued by 88.54% relative to our estimate of its Fair Value price of $6.06 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
PXMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PXMD due diligence checks available for Premium users.
Be the first to know about important PXMD news, forecast changes, insider trades & much more!
PXMD News
Valuation
PXMD fair value
Fair Value of PXMD stock based on Discounted Cash Flow (DCF)
Price
$0.69
Fair Value
$6.06
Undervalued by
88.61%
PXMD ($0.69) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PXMD ($0.69) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PXMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PXMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.03x
Industry
11.7x
Market
31.32x
PXMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-2.96x
Industry
5.42x
PXMD's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.0M
Profit Margin
0%
PXMD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$3.2M
Liabilities
$3.8M
Debt to equity
-7.02
PXMD's short-term liabilities ($3.27M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PXMD's short-term assets ($3.23M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PXMD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PXMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.3M
Investing
$0.0
Financing
$414.9k
PXMD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PXMD vs Biotech Stocks
Paxmedica Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.